Perturbing ROS homeostasis or inhibition of NOX1 reduced tumor growth and angiogenesis in vivo and could represent a new possible therapeutic approach in LKB1-deficient KRAS-mutated tumors. The gene discussed is KRAS; the disease is neoplasm.